Show simple item record

dc.contributor.authorLuzuriaga, Katherine
dc.contributor.authorMcManus, Margaret M.
dc.contributor.authorCatalina, Michelle D.
dc.contributor.authorMayack, Shane Renee
dc.contributor.authorSharkey, Mark E.
dc.contributor.authorStevenson, Mario
dc.contributor.authorSullivan, John L.
dc.date2022-08-11T08:09:34.000
dc.date.accessioned2022-08-23T16:35:58Z
dc.date.available2022-08-23T16:35:58Z
dc.date.issued2000-07-11
dc.date.submitted2009-03-26
dc.identifier.citationJ Virol. 2000 Aug;74(15):6984-91.
dc.identifier.issn0022-538X (Print)
dc.identifier.pmid10888637
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38679
dc.description.abstractStudies of potent antiretroviral combination regimens were undertaken in young infants to evaluate the potential for long-term suppression of viral replication and to evaluate the immune consequences of such therapies. Early combination antiretroviral therapy led to a loss of plasma viremia, cultivable virus, and labile extrachromosomal replication intermediates. Despite preservation of immune function, persistent human immunodeficiency type 1 (HIV-1)-specific immune responses were not detected in most infants. The absence of detectable, persisting immune responses in most HIV-1-infected infants treated early contrasts with what is typically seen in adults who are treated early. These results are consistent with the notion that early combination antiretroviral therapy of HIV-1-infected infants allows the long-term suppression of viral replication.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=10888637&dopt=Abstract">Link to Article in PubMed</a>
dc.subjectAnti-HIV Agents
dc.subjectCD4 Lymphocyte Count
dc.subjectChild, Preschool
dc.subjectDisease Transmission, Vertical
dc.subjectDrug Therapy, Combination
dc.subjectHIV Antibodies
dc.subjectHIV Infections
dc.subjectHIV-1
dc.subjectHumans
dc.subjectInfant
dc.subjectInfant, Newborn
dc.subjectLymphocyte Activation
dc.subjectRNA, Viral
dc.subjectReverse Transcriptase Inhibitors
dc.subjectT-Lymphocytes, Cytotoxic
dc.subjectViral Load
dc.subjectVirus Replication
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleEarly therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses
dc.typeJournal Article
dc.source.journaltitleJournal of virology
dc.source.volume74
dc.source.issue15
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2534&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1535
dc.identifier.contextkey798511
refterms.dateFOA2022-08-23T16:35:58Z
html.description.abstract<p>Studies of potent antiretroviral combination regimens were undertaken in young infants to evaluate the potential for long-term suppression of viral replication and to evaluate the immune consequences of such therapies. Early combination antiretroviral therapy led to a loss of plasma viremia, cultivable virus, and labile extrachromosomal replication intermediates. Despite preservation of immune function, persistent human immunodeficiency type 1 (HIV-1)-specific immune responses were not detected in most infants. The absence of detectable, persisting immune responses in most HIV-1-infected infants treated early contrasts with what is typically seen in adults who are treated early. These results are consistent with the notion that early combination antiretroviral therapy of HIV-1-infected infants allows the long-term suppression of viral replication.</p>
dc.identifier.submissionpathoapubs/1535
dc.contributor.departmentProgram in Molecular Medicine
dc.contributor.departmentDepartment of Pediatrics
dc.source.pages6984-91


Files in this item

Thumbnail
Name:
10888637.pdf
Size:
136.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record